ArcelorMittal Announces the Publication of First Quarter 2012 EBITDA Sell-Side Analyst Consensus Figures on www.arcelormittal.com
Regulatory News:
The consensus figures are based on analyst estimates recorded on an external web based tool to be provided and managed by an independent company called Vuma Financial Services Limited (trade name: Vuma Consensus).
To arrive at the consensus figures below, VUMA have aggregated the expectations of sell side analysts who, to our best knowledge, cover ArcelorMittal on a continuous basis. This is a group of about 30 brokers currently. The listed analysts follow ArcelorMittal on their own initiative and ArcelorMittal is not responsible for their views.
On this page we provide you with the analyst estimates compiled by Vuma Consensus, and ArcelorMittal is neither involved in the collection of the information nor in the compilation of the estimates.
The consensus data is based on projections made by sell-side analysts. The sell-side analysts who cover ArcelorMittal and whose estimates are included in the group consensus outlined above are the following:
- BarclaysCapital - Vincent Lepine
- Bank of America Merrill Lynch - Cedar Barnes
- BHF Bank - Hermann Reith
- Caja Madrid - Iñigo Recio
- Citigroup - Anindya Mohinta
- Commerzbank, Ingo Schachel
- Credit Suisse, Michael Shillaker
- Dahlman Rose & Co., Anthony Rizzuto Jr.
- Davy - Killian Murphy, Tim Cahill
- Deutsche Bank - David Martin, Bastian Synagowitz
- Exane BNP Paribas - Sylvain Brunet, Luc Pez
- Grupo Santander - Nitesh Agarwal , Juan Ramon Correas
- HSBC - Thorsten Zimmermann
- JP Morgan - Alessandro Abate
- Kempen - Sander van Oort
- Kepler Capital Markets - Rochus Brauneiser
- Macquerie Bank – Jeff Largey
- Natexis – Raoudha Bouzekri
- Nomura - Neil Sampat
- Petercam - Alan Vandenberghe
- RBC - Tim Huff
- Societe Generale - Alain William
- UBS - Carsten Reik.
Disclaimer
The consensus estimate is based on
estimates, forecasts and predictions made by third party financial
analysts. It is not prepared based on information provided or checked by
ArcelorMittal and can only be seen as a consensus view on
ArcelorMittal's results from an outside perspective. ArcelorMittal has
not provided input on these forecasts, except by referring to past
publicly disclosed information. ArcelorMittal does not accept any
responsibility for the quality or accuracy of any individual forecast or
estimate. This web page may contain forward-looking statements based on
current assumptions and forecasts made by ArcelorMittal or third
parties. Various known and unknown risks, uncertainties and other
factors could lead to material differences between ArcelorMittal's
actual future results, financial situation, development or performance,
and the estimates given here. These factors include those discussed in
ArcelorMittal's periodic reports available on
www.arcelormittal.com
.
About ArcelorMittal
ArcelorMittal is the world's leading steel and mining company, with a presence in more than 60 countries.
ArcelorMittal is the leader in all major global carbon steel markets, including automotive, construction, household appliances and packaging, with leading R&D and technology. The Group also has a world class mining business with a global portfolio of over 20 mines in operation and development, and is the world’s 4th largest iron ore producer. With operations in over 22 countries spanning four continents, the Company covers all of the key industrial markets, from emerging to mature, and has outstanding distribution networks.
Through its core values of sustainability, quality and leadership, ArcelorMittal commits to operating in a responsible way with respect to the health, safety and well-being of its employees, contractors and the communities in which it operates. It is also committed to the sustainable management of the environment. It takes a leading role in the industry's efforts to develop breakthrough steelmaking technologies and is actively researching and developing steel-based technologies and solutions that contribute to combat climate change. ArcelorMittal is a member of the FTSE4Good Index and the Dow Jones Sustainability World Index.
In 2011, ArcelorMittal had revenues of $94.0 billion and crude steel production of 91.9 million tonnes, representing approximately 6 per cent of world steel output. The Group's mining operations produced 54 million tonnes of iron ore and 8 million tonnes of metallurgical coal.
ArcelorMittal is listed on the stock exchanges of New York (MT), Amsterdam (MT), Paris (MT), Luxembourg (MT) and on the Spanish stock exchanges of Barcelona, Bilbao, Madrid and Valencia (MTS).
For more information about ArcelorMittal visit: www.arcelormittal.com
Contact:
Contact information ArcelorMittal Investor Relations
Europe
+ 352 4792 2484
Americas + 1 312 899 3569
Retail + 44 203 214
3198
SRI + 44 207 543 1128
Bonds/Credit + 33 171 92 10 26
or
Contact
information ArcelorMittal Corporate Communications
E-mail: press@arcelormittal.com
Phone:
+352 4792 5000
or
ArcelorMittal Corporate Communications
Giles
Read (Head of Media Relations) + 44 20 3214 2845
Lynn Robbroeckx +
44 20 3214 2991
Tobin Postma + 44 20 3214 2412
or
United
Kingdom
Maitland Consultancy:
Rebecca Mitchell
/
Martin Leeburn + 44 20 7379 5151
or
France
Image 7
Sylvie
Dumaine / Anne-Charlotte Creach + 33 1 5370 7470
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom